This document introduces a feasibility study of a capillary electrophoresis-mass spectrometry (CE-MS) technique for toxicological drug screening in blood samples. The study shows that the Agilent LC/MSD Trap system can detect drugs at levels as low as 20 ng/mL in whole blood, suggesting that it may be a suitable tool for screening whole blood samples for drugs. Additionally, the system's capability of generating MSn data allows reliable identification of detected drugs, suggesting that both screening and identification of drugs can be accomplished in one or two injections using the same instrument system.
The document presents a feasibility study on detecting and identifying drugs in whole blood samples using Capillary Electrophoresis-Mass Spectrometry (CE-MS). The authors utilize an Agilent G1600A 3D CE coupled to an Agilent LC/MSD Trap XCT system. Preliminary observations indicate that this setup can detect drugs at concentrations less than 20 ng/mL, suggesting its suitability for toxicological screening.
| Capillary length to DAD | 21.5 cm |
|---|---|
| Capillary length to LC/MSD Trap | 84.0 cm |
| Diode array wavelength | 375 nm, bandwidth 75 nm |
The system can detect drugs at concentrations less than 20 ng/mL in whole blood.
Yes, generating MS" data permits reliable identification of detected drugs, allowing both screening and identification in one or two injections.
No, the study suggests that matrix components extracted from whole blood do not offer serious obstacles to MS analysis.